{
  "id": "5c6585287c78d69471000004",
  "type": "list",
  "question": "For which indications has midostaurin received FDA and EMA approval?",
  "ideal_answer": "Midostaurin was approved by the Food and Drug Administration (FDA) and the European Medical Agency (EMA) for acute myeloid leukemia with activating FLT3 mutations in combination with intensive induction and consolidation therapy as well as aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) or mast cell leukemia (MCL).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/30069632"
  ],
  "snippets": [
    {
      "text": "Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30069632",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Midostaurin was approved by the Food and Drug Administration (FDA) and the European Medical Agency (EMA) for acute myeloid leukemia with activating FLT3 mutations in combination with intensive induction and consolidation therapy as well as aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN) or mast cell leukemia (MCL).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30069632",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Acute myeloid leukemia with activating FLT3 mutations, Aggressive systemic mastocytosis, Systemic mastocytosis with associated hematological neoplasm, Mast cell leukemia"
}